Hansa Biopharma AB's ROE % for the quarter that ended in Mar. 2026 was 0.00%. Hansa Biopharma AB's PB Ratio for the quarter that ended in Mar. 2026 was N/A.
Hansa Biopharma AB's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was N/A.
Hansa Biopharma AB ROE % Adjusted to Book Value Related Terms
Hansa Biopharma AB ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Hansa Biopharma AB's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hansa Biopharma AB ROE % Adjusted to Book Value Chart
OSTO:HNSA vs VRTX, REGN, ALNY: ROE % Adjusted to Book Value Comparison
For the Biotechnology subindustry, Hansa Biopharma AB's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hansa Biopharma AB ROE % Adjusted to Book Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hansa Biopharma AB's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Hansa Biopharma AB's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of 0.00% mean?
Hansa Biopharma AB (OSTO:HNSA) has a ROE % Adjusted to Book Value of 0.00% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Hansa Biopharma AB and its competitors.
Is Hansa Biopharma AB's ROE % Adjusted to Book Value too high?
Hansa Biopharma AB's current ROE % Adjusted to Book Value is 0.00%. Overall, Hansa Biopharma AB has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hansa Biopharma AB's ROE % Adjusted to Book Value compare to VRTX and REGN?
Hansa Biopharma AB's ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Hansa Biopharma AB and its competitors. Hansa Biopharma AB's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansa Biopharma AB stock overvalued right now?
Based on GuruFocus' analysis, Hansa Biopharma AB (OSTO:HNSA) is currently considered Significantly Overvalued. The stock's GF Value™ is kr24.51, compared to a current price of kr34.88 — trading 42.3% above its estimated fair value. The current ROE % Adjusted to Book Value is 0.00%. Hansa Biopharma AB's overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Hansa Biopharma AB (OSTO:HNSA), the current ROE % Adjusted to Book Value is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hansa Biopharma AB (OSTO:HNSA) Overvalued in 2026?
Based on GuruFocus' analysis, Hansa Biopharma AB stock appears to be overvalued.
The current stock price of kr34.88 is trading 42.3% above its estimated GF Value™ of kr24.51.
GuruFocus considers Hansa Biopharma AB to be Significantly Overvalued.
Key valuation signals for OSTO:HNSA:
ROE % Adjusted to Book Value: 0.00%
GF Value™: kr24.51 vs. price of kr34.88 (42.3% above fair value)
No single metric tells the full story. See the OSTO:HNSA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hansa Biopharma AB is a commercial-stage biopharmaceutical company pioneering the development and commercialization of life-saving and life-altering therapies for patients with rare immunological conditions. It has developed a proprietary, first-in-class antibody-cleaving enzyme technology platform designed to eliminate pathogenic IgG antibodies. This differentiated platform supports a broad pipeline with potential applications across Transplantation, Autoimmune diseases, and Gene Therapy-areas characterized by unmet medical need. Hansa's first-generation IgG-cleaving enzyme, imlifidase, is designed to inactivate all four IgG subclasses (IgG1, IgG2, IgG3, and IgG4) in both the intravascular and extravascular compartments following a single intravenous administration.
50GF Score
Get the complete analysis for OSTO:HNSA
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:HNSA has been successfully added to your 
